A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Listed as NCT04569032, this PHASE2 trial focuses on Peripheral T-cell Lymphoma and remains completed. Sponsored by Seagen, a wholly owned subsidiary of Pfizer, it has been updated 43 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
43 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 38 earlier versions
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Seagen, a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .